Multiple Myeloma News

News

Cost-Effectiveness of Daratumumab or Bortezomib Added to Lenalidomide Plus Dexamethasone in Newly Diagnosed MM

03/01/2022

Neither daratumumab nor bortezomib added to lenalidomide plus dexamethasone are cost-effective vs lenalidomide and dexamethasone alone for patients with newly diagnosed MM, according to a recent study.

Neither daratumumab nor...

03/01/2022

Journal of Clinical Pathways

News

Comparing Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM

11/08/2021

Marta Rybczynski ;

Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve PFS for newly diagnosed MM, compared to maintenance alone.

Consolidation treatment with...

11/08/2021

Journal of Clinical Pathways

News

Belantamab Mafodotin Cost-Effective for Relapsed/Refractory MM

09/21/2021

Study findings suggest that belantamab mafodotin is associated with lower costs and increased quality-adjusted life years compared to selinexor plus dexamethasone for patients with relapsed/refractory MM.

Study findings suggest that...

09/21/2021

Journal of Clinical Pathways

News

Cost-Effectiveness of Adding Daratumumab to Chemotherapy for Newly Diagnosed MM

08/03/2021

Adding daratumumab to bortezomib, melphalan, and prednisone is considered more cost-effective than bortezomib, melphalan, and prednisone alone for newly diagnosed MM.

Adding daratumumab to...

08/03/2021

Journal of Clinical Pathways

News

DRd Improves PROs Compared With Rd for Newly Diagnosed MM

02/01/2021

Journal of Clinical Pathways

News

NGS Comparable to NGF for Assessing MRD in Patients With MM

12/02/2020

Journal of Clinical Pathways

News

Treatment Pattern, Outcome Disparities in Older Patients With Newly Diagnosed MM

11/18/2020

Journal of Clinical Pathways

News

Treatment Burden of Newly Diagnosed MM

11/11/2020

Journal of Clinical Pathways

News

Real-World Treatment Patterns and Outcomes in Relapsed/Refractory MM

10/28/2020

Journal of Clinical Pathways

News

Care Model Beneficial for Estimating Impact of MM Treatment on Payers

09/22/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Multiple Myeloma News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products